Hayes receives 2026 ESMO Breast Cancer Award
11:00 AM
Daniel F. Hayes, M.D., was selected by the European Society for Medical Oncology, ESMO, for the 2026 ESMO Breast Cancer Award.
Hayes, Stuart B. Padnos Professor of Breast Cancer Research (Active Emeritus) at the University of Michigan Rogel Cancer Center, is recognized for his exceptional contributions to experimental therapeutics and cancer biomarker research in breast cancer. His work has focused particularly on the development and validation of biomarker tests such as HER2, CA15‑3, circulating tumor cells and pharmacogenomic markers. He has also played a pivotal role in establishing international guidelines for the use of tumor biomarker tests, including defining criteria to assess their clinical utility.
He will deliver his award lecture, titled “Reflections on a Life-time of Liquid Biopsy Research in Breast Cancer,” during the opening session of the ESMO Breast Cancer 2026 congress, on May 6.
Featured News & Stories
Health Lab
5-year survival rate has increased for all cancers, according to American Cancer Society
The American Cancer Society reports that mortality rates have continued to decline since the 1990s. N. Lynn Henry, of Michigan Medicine, answers questions about how factors such as healthy lifestyle choices, early screening and clinical trials have improved cancer survival rates.
Health Lab
Breast cancer patient encourages women to commit to their health
A Michigan Medicine patient learned as a young woman that she had a BRCA1 mutation. Her dedication to yearly mammograms helped her catch her cancer early.
Health Lab
What is ductal carcinoma in situ breast cancer?
A Michigan Medicine breast cancer expert discusses diagnosis, treatment and risk factors of Ductal Carcinoma In Situ (DCIS) and what you should know.
Health Lab
Patients are opting in for 10 years of breast cancer treatment
As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a recent study sheds light on whether patients are opting for it.
Health Lab
Drug combination reduces breast cancer risk and improves metabolic health in rats
Researchers investigated the combined effects of bazedoxifene and conjugated estrogens in rat models as an alternative to tamoxifen.
Health Lab
Finding a 'beautiful gift' within stage 4 lung cancer
How one woman found 'a beautiful gift' within stage 4 lung cancer.
